Payment overview · 2025
General Payments
$1,315.24
60 reported records · 22 companies
Healthcare provider profile · identity verified
Jason Fishbein, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BETHPAGE, NY · NPI 1972602555
Verified facts
What the public records show
CMS Open Payments records show Jason Fishbein, M.D. received $1,315.24 in general payments during 2025 across 60 reported records.
Lilly USA, LLC accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $209.14 | 15.9% | 11 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$155.63 | 11.8% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $125.26 | 9.5% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $98.15 | 7.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.74 | 6.8% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.41 | 6.5% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $67.68 | 5.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.28 | 4.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.62 | 4.6% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $52.09 | 4.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.12 | 3.7% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $44.35 | 3.4% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $36.33 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.74 | 1.9% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $24.57 | 1.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.65 | 1.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $23.22 | 1.8% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $19.74 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.30 | 1.5% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.13 | 1.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.26 | 1.1% | 1 | 2025 |
| Spinal Elements, INC. | Unresolved — no canonical attribution shown | $12.83 | 1.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,315.24 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $177.28 | 9 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $155.63 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $125.26 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $110.99 | 6 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $85.41 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $62.28 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.03 | 3 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $52.09 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $48.12 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $44.35 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.97 | 2 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $39.64 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $36.33 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.59 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.31 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| Medical Device Normalized: medical device |
Device | Spinal Elements, INC. | $12.83 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 428 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 420 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 92 |
| Losartan Potassium | Losartan Potassium | 232 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 213 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 48 |
| Metformin Hcl Er | Metformin Hcl | 136 | 45 |
| Omeprazole | Omeprazole | 118 | 38 |
| Lisinopril | Lisinopril | 117 | 38 |
| Simvastatin | Simvastatin | 109 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 29 |
| Valsartan | Valsartan | 97 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 31 |
| Metformin Hcl | Metformin Hcl | 70 | 20 |
| Synthroid | Levothyroxine Sodium | 66 | 20 |
| Furosemide | Furosemide | 61 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 18 |
| Alprazolam | Alprazolam | 59 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 15 |
| Sertraline Hcl | Sertraline Hcl | 55 | 16 |
| Jardiance | Empagliflozin | 52 | 16 |
| Famotidine | Famotidine | 48 | 17 |
| Ezetimibe | Ezetimibe | 46 | 17 |
| Ramipril | Ramipril | 46 | 17 |
| Gabapentin | Gabapentin | 45 | 18 |
| Glimepiride | Glimepiride | 45 | 14 |
| Irbesartan | Irbesartan | 43 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 12 |
| Atenolol | Atenolol | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | 17 |
| Trazodone Hcl | Trazodone Hcl | 37 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Carvedilol | Carvedilol | 30 | 11 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Eliquis | Apixaban | 28 | 13 |
| Januvia | Sitagliptin Phosphate | 27 | 12 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Enulose | Lactulose | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Mupirocin | Mupirocin | 13 | 11 |
| Ozempic | Semaglutide | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Prednisone | Prednisone | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,315.24 · 60 records | Lilly USA, LLC | Auvelity, COSENTYX, CRENESSITY, Cologuard Collection Kit, EVENITY, Exablate, INSPIRE, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, LEQVIO, Leqembi, MINIMED 780G, MOUNJARO, Medical Device, Omnipod, Ozempic, PROLIA, RECORLEV, RINVOQ, Rybelsus, SPRAVATO, TEPEZZA, TRELEGY ELLIPTA, UNITHROID, Wegovy, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error